Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study

References

• Kakinuma T, Nakamura K, Wakugawa M, et al. Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis. Clin Exp Immunol. 2002;127:270–273.
   PubMed Web of Science ®Google Scholar
• Odhiambo JA, Williams HC, Clayton TO, et al. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124:1251–1258 e23.
   PubMed Web of Science ®Google Scholar
• Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine 2015;73:311–318.
   PubMed Web of Science ®Google Scholar
• Bülow AV, Backer V, Bodtger U, et al. S8 A nationwide real-life study: exploring the difficulties of confirming the asthma diagnosis in patients with severe asthma. Thorax 2015;70:A8.
   Web of Science ®Google Scholar
• Park JH, Choi YL, Namkung JH, et al. Characteristics of extrinsic vs. intrinsic atopic dermatitis in infancy: correlations with laboratory variables. Br J Dermatol. 2006;155:778–783.
   PubMed Web of Science ®Google Scholar
• Tokura Y. Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci. 2010;58:1–7.
   PubMed Web of Science ®Google Scholar
• Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy 2012;67:1475–1482.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102:558–562.
   PubMed Web of Science ®Google Scholar
• Bae JM, Choi YY, Park CO, et al. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;132:110–117.
   PubMed Web of Science ®Google Scholar
• Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011;127:18–27.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Bachert C, Bousquet PJ, et al. GA 2 LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy. 2010;65:1525–1530.
   PubMed Web of Science ®Google Scholar
• Pipet A, Botturi K, Pinot D, et al. Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy. Res Med. 2009;103:800–812.
   PubMed Web of Science ®Google Scholar
• Bonadonna P, Zanotti R, Caruso B, et al. Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. J Allergy Clin Immunol. 2008;121:256–257.
   PubMed Web of Science ®Google Scholar
• Lawrence MG, Steinke JW, Borish L. Basic science for the clinician: mechanisms of sublingual and subcutaneous immunotherapy. Ann Allergy Asthma Immunol. 2016;117:138–142.
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Compalati E, Canonica GW. Sublingual immunotherapy: clinical indications in the WAO-SLIT position paper. World Allergy Organ J. 2010;3:216–219.
   PubMedGoogle Scholar
• Saleh AM, Ali HA, Ahmed SA, et al. House dust mites: a risk factor to be considered for occupational safety or source of work-related allergens. JESP. 2013;43:669–678.
   Google Scholar
• Qin YE, Mao JR, Sang YC, et al. Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. Int J Dermatol. 2014;53:650–655.
   PubMed Web of Science ®Google Scholar
• Schäfer T, Dockery D, Krämer U, et al. Severity scoring of atopic dermatitis (SCORAD). Allergo J. 1997;6:410–410.
   Google Scholar
• Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy. 1986;16:483–491.
   PubMedGoogle Scholar
• Cadario G, Galluccio AG, Pezza M, et al. Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study. Curr Med Res Opin. 2007;23:2503–2506.
   PubMed Web of Science ®Google Scholar
• Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007;120:164–170.
   PubMed Web of Science ®Google Scholar
• Tam H, Calderon MA, Manikam L, et al. Specific allergen immunotherapy for the treatment of atopic eczema. Cochrane Database Syst Rev. 2016;122:CD008774.
   Google Scholar
• Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy. 1992;22:440–446.
   PubMed Web of Science ®Google Scholar
• Prakash A, Benfield P. Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs 1998;55:145–163.
   PubMed Web of Science ®Google Scholar
• Justicia JL, Barasona MJ, Serrano P, et al. Predicting patients at high-risk of systemic reactions to cluster allergen immunotherapy: a pilot prospective observational study. J Investig Allergol Clin Immunol. 2007;17:386–392.
   PubMed Web of Science ®Google Scholar
• Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112:S118–S27.
   PubMed Web of Science ®Google Scholar